Across TCGA pan-cancer cohorts, KEL Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KEL data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KEL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KEL expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, UCEC, and PRAD are the cancer types where KEL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.091	0.531	.001	15	view →
UCEC	DFS	Median	II,III,IV	0.875	0.432	.028	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.101	0.632	.011	3	view →
SKCM	DFS	Median	II,III,IV	0.804	0.653	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: KEL tumor-vs-normal RNA expression · all KEL data types